The nature of the green medical doctor is that of a shaman.
He guides the forces of healing from many disciplines and
dimensions. A shaman-doctor learns to navigate these forces
for the benefit of the patient and he is aware of the subtle healing secrets
of ethno-botanical medicines.
A green medical doctor is a shaman that integrates the healing
forces of many societies and cultures.
Shamanism and green medicine are the future of progressive health and longevity!
FDA consumer magazine: the renewal of psychedelic research*
Journal of Psychoactive drugs: The use of Cannabis as a mood stabilizer*
British Medical Journal: Cannabis the wonder drug*
Los Angeles Times: Puffing is the best medicine*
Here are some more of the articles:
Chicago Tribune:
Truth and Medical Marijuana
Boston Globe:
Judge: Lets professor grow medicinal marijuana
San Francisco Chronicle:
Judge sides with botanist on pot supply
The Miami Herald:
Judge rules government supply of marijuana is inadequate
Austin Chronicle:
Reefer Madness: Judge Supports Bid to Grow Research Pot
February 13, 2007. The Washington Post reported in "Research Supports Medicinal Marijuana" on Dr. Donald Abrams' double-blind study of smoked marijuana for HIV-related peripheral neuropathy that was published in the respected journal Neurology. The findings showed that marijuana can be a safe and effective medication for many people with this condition, and is evidence of marijuana's therapeutic potential. Yet, no researchers are continuing Dr. Abrams' promising research, because NIDA's monopoly and arbitrary review process deters any private sponsor from investing in a medical marijuana drug development effort.
January 31, 2007. Reuters reported in "Smokable Pain Drugs Promise Faster Action" on Alexza's development of smokeable drugs for migraine, pain, panic and agitation. This development could have implications for research with medical marijuana, since one of the government's main arguments has been that no legitimate medicine is smoked.
December 11, 2006. Today's BBC News features an article describing Dr. Francisco Moreno's Heffter- and MAPS-sponsored research at the Univ. of Arizona-Tucson evaluating psilocybin-assisted psychotherapy as treatment for individuals suffering from treatment-resistant Obsessive-Compulsive Disorder (OCD). Dr. Moreno recently published his findings in the Journal of Clinical Psychiatry.
December 8, 2006. While in Thailand to testify in a medical MDMA trial, MAPS President Rick Doblin took the opportunity to do an interview with The Nation, Thailand's largest English-language daily newspaper. In the interview, Doblin speculates on the possibility of conducting MDMA/PTSD research with tsunami victims and discusses MAPS' international psychedelic research agenda.
December 6, 2006. Prague's largest English daily, The Prague Post, reported today in "Long, Strange Trip" on MAPS-sponsored long-term follow-up research with Czechoslovak patients that were treated with LSD as part of a government-sponsored program between 1956-1974. A proposed MAPS-sponsored LSD-assisted psychotherapy study in Switzerland could soon become the first LSD research in the world in 35 years.
December 1, 2006. "This American Life" on National Public Radio features a story about a former heroin addict who has been treating people addicted to heroin with the psychedelic drug ibogaine. MAPS is currently sponsoring an IRB-approved long-term observational case study of ibogaine treatments at the Iboga Therapy House in Vancouver, Canada.
November 19, 2006. The LA Times ran "Mushrooms Take a Trip Back to the Lab," on the front page of its Sunday edition. The article describes MAPS-initiated research at Harvard/Mclean Hospital evaluating psilocybin as treatment for cluster headache, Dr. Charles Grob's psilocybin/end-of-life anxiety pilot study at UCLA, and the recent Johns Hopkins study demonstrating that psilocybin induces mystical experiences. MAPS is in the early stages of protocol design for a study evaluating psyilocybin-assisted psychotherapy as a potential treatment for end-of-life anxiety. Unfortunately, although the article is mostly accurate, Times Staff writer Denise Gellene misleadingly prefaces her article by stating, "Nothing scientists have learned so far indicates that recreational use of mushrooms is safe," a far cry from the truth.
Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 39 (1):13-19.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006 Nov;67(11):1735-40.
Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58:624–631.